• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:50:36 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care
    Get the next $SNSS alert in real time by email
    SC 13G/A 1 tm216476d18_sc13ga.htm SCHEDULE 13G/A

     

     

     

    CUSIP No:   867328874

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Sunesis Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    867328874

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

     *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No:   867328874

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands

     

    NUMBER OF   (5) SOLE VOTING POWER
           
    SHARES     0
           
    BENEFICIALLY   (6) SHARED VOTING POWER **
           
         

    0

    OWNED BY      
           
    EACH   (7) SOLE DISPOSITIVE POWER
           
    REPORTING     0
           
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
           
         

    0

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    0

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
        0%
         
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:   867328874

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
       
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
       
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware

     

    NUMBER OF   (5) SOLE VOTING POWER
     
    SHARES     0
     
    BENEFICIALLY   (6) SHARED VOTING POWER **
     
    OWNED BY    

    0

         

     

    EACH   (7) SOLE DISPOSITIVE POWER
     
    REPORTING     0
         
     
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
     
         

    0

     

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    0

         
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT
      IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
       
       
    (11) PERCENT OF CLASS REPRESENTED
      BY AMOUNT IN ROW (9)
     
        0%
         
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:   867328874

     

    Item 1.

     

    (a)Name of Issuer
      
     Sunesis Pharmaceuticals, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices
      
     395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080

     

    Item 2(a).Name of Person Filing
      
     This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT 

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250 

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number

     

    867328874

     

     

     

     

    CUSIP No:   867328874

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

     

     

     

    CUSIP No:   867328874

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control

    Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No:   867328874

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021    
         
         
    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of   Name:  Brian Sopinsky
    Attorney, a copy of which was   Title:  Secretary
    previously filed      
       
    By: /s/ Brian Sopinsky    
    Name:  Brian Sopinsky    
    Title:  Secretary    
             

     

     

     

     

    CUSIP No:   867328874

     

    EXHIBIT INDEX

     

    EXHIBIT DESCRIPTION
    I Limited Power of Attorney*
    II Joint Filing Agreement*
       
    * Previously filed 

     

     

    Get the next $SNSS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by J. Barry Simon

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:46:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by Stephen Rubino

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:42:13 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock

      3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)

      2/25/21 6:09:20 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Market Perform to Outperform and set a new price target of $12.00

      3/1/21 8:39:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Perform to Outperform and set a new price target of $12.00

      2/23/21 5:59:10 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

      3/4/21 4:06:03 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 8-K filed

      8-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 4:34:51 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K filed

      10-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 6:06:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

      SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the trea

      2/16/21 8:00:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

      SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021 and the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. The Company will present and participate in one-on-one investor meetings at both conferences. Details on the events can be found below. LifeSci Partners Precision Oncology Day Date: Wednesday, February 17, 2021 Time: 2:30 PM ET Format: Corporate presentation 10th Annual SVB Leerink Globa

      2/11/21 4:05:00 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

      SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas. At the 62nd American Society of Hematology (ASH) Annual Meeting, Dr. Pierluigi Porcu of Sidney Kimmel Cancer Center, Thomas Jefferson University, presented updated data from Viracta's ongoing clinical trial evaluating its all-oral combination regimen of nanatinostat and valganciclovir for the treatment of patients with R/R EBV+ lymphoma that had failed one or more prior therapies

      12/7/20 8:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Financials

    Live finance-specific insights

    See more
    • Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

      Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have approximately $120 million cash balance following the close of the merger Companies to host conference call today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta

      11/30/20 7:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed

      SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/10/21 9:40:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/8/21 5:05:56 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/5/21 1:30:27 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care